logo-loader
viewPreveCeutical Medical Inc

PreveCeutical receives refund from Australian Taxation Office for R&D work Down Under

It received a cash refund of nearly A$617,000 from the Australian Taxation Office’s Research and Development Tax Incentive Program

australian dollars
The cash refund is for expenditures on eligible R&D activities conducted in Australia during the 2018 financial year

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) announced Monday that it has received a tax credit from the Australian government for the pharmaceutical company’s 2018 research and development program in the country. 

The Vancouver-based company received a cash refund of nearly A$617,000 from the Australian Taxation Office’s Research and Development Tax Incentive Program.

PreveCeutical is studying its Sol-gel nose-to-brain drug delivery system and non-addictive pain medication at the University of Queensland in the country.

READ: PreveCeutical completes efficacy screening of small interfering RNA-based therapy for type 2 diabetes

The cash refund is for expenditures on eligible R&D activities conducted in Australia during the 2018 financial year.

"We are highly supportive of the Australian Government's R&D Tax Credit incentive which recognizes the critical role of R&D involved in potentially developing life-saving drugs, therapies and delivery devices,” PreveCeutical’s president and chief science officer Dr Mak Jawadekar said in a statement on Monday.

The refund will help enable PreveCeutical to further advance proprietary therapeutic alternatives for preventive and curative therapies for unmet medical needs, Jawadekar told investors.

Australia’s R&D Tax Incentive Program encourages companies to conduct R&D programs in the country, including those with the potential to improve global health outcomes.

PreveCeutical opened its Australian subsidiary in March 2018 to advance the development of the company’s therapeutic technologies.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: PreveCeutical Medical Inc

Price: 0.03 CAD

CSE:PREV
Market: CSE
Market Cap: $11.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...

on 26/4/19

2 min read